Drug Profile
Psilocybin - Cybin
Alternative Names: CYB 001; INT0052/2020Latest Information Update: 26 Oct 2022
Price :
$50
*
At a glance
- Originator Cybin
- Developer Cybin; University of Washington
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Anxiety disorders
Highest Development Phases
- Phase II Mental disorders
- Phase I Major depressive disorder
- Discontinued Anxiety disorders
Most Recent Events
- 20 Oct 2022 IntelGenx Corp has patent protection for VersaFilm® oral film technology in the US
- 08 Apr 2022 Cybin has international patents pending for psilocybin and other psychedelic compounds
- 10 Feb 2022 Phase-I clinical trials in Mental disorders in USA (Sublingual) before February 2022 (Cybin's pipeline, February 2022)